Novartis' CDK4/6 inhibitor Kisqali has claimed a broad FDA approval in early breast cancer that could give it an edge over class rival Verzenio from Eli Lilly. The US regulator has cleared Kisqali ...
Eli Lilly’s Verzenio breast cancer drug has been approved in Europe, as the pharma prepares to compete with established rivals from Pfizer and Novartis. Verzenio (abemaciclib) is a CDK4 and 6 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback